cmAngio™
Slider

Find. Score. Assess

cmAngio™ An investigational
AI-based triage software that helps doctors assess a patient’s risk of coronary heart disease (CHD).

cmAngio produces a CureMetrix Bradley ScoreTM based on the existence and characteristics of breast arterial calcifications in the mammogram. This proprietary score can then be used to help the care team assess the patient’s risk of CHD directly from their mammogram. The Bradley Score and their associated risk of CHD can be tracked over time to help patients and doctors understand their changing health profile.

Once validated, cmAngio can be used as a clinical decision support tool that will enable physicians and healthcare teams to:

  • Identify women with a risk of coronary heart disease identified during routine      breast cancer screening using mammography
  • Enable clinical protocols that allow women at risk to be seen by their primary care physicians or cardiologists
  • Help identify women who are at risk and might otherwise have gone undiagnosed until other more serious symptoms became apparent

Ultimately reduce costs in the healthcare system and potentially save lives.

cmAngio Key Features

SOURCES
CDC: National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention www.cdc.gov/heartdisease/women.htm
American Heart Association www.heart.org/idc/groups/heart-public/@wcm/@sop/@smd/documents/downloadable/ ucm_319576.pdf
American Cancer Society www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer
1American Heart Association
www.ahajournals.org/journal/circ
A Review of the Role of Breast Arterial Calcification for Cardiovascular Risk Stratification in Women. Circulation. 2019;139:1094–1101. DOI: 10.1161/CIRCULATIONAHA.118.038092